Your browser doesn't support javascript.
loading
Reduced Likelihood of Hospitalization with the JN.1 or HV.1 SARS-CoV-2 Variants Compared to the EG.5 Variant.
Levy, Matthew E; Chilunda, Vanessa; Davis, Richard E; Heaton, Phillip R; Pawloski, Pamala A; Goldman, Jason D; Schandl, Cynthia A; McEwen, Lisa M; Cirulli, Elizabeth T; Wyman, Dana; Rossi, Andrew Dei; Dai, Hang; Isaksson, Magnus; Washington, Nicole L; Basler, Tracy; Tsan, Kevin; Nguyen, Jason; Ramirez, Jimmy; Sandoval, Efren; Lee, William; Lu, James; Luo, Shishi.
Affiliation
  • Levy ME; Helix, San Mateo, California, USA.
  • Chilunda V; Helix, San Mateo, California, USA.
  • Davis RE; Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, USA.
  • Heaton PR; Department of Pathology and Laboratory Medicine, HealthPartners, Bloomington, Minnesota, USA.
  • Pawloski PA; HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Goldman JD; Swedish Center for Research and Innovation, Providence Swedish Medical Center, Seattle, Washington, USA.
  • Schandl CA; Division of Allergy and Infectious Disease, University of Washington, Seattle, Washington, USA.
  • McEwen LM; Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Cirulli ET; Helix, San Mateo, California, USA.
  • Wyman D; Helix, San Mateo, California, USA.
  • Rossi AD; Helix, San Mateo, California, USA.
  • Dai H; Helix, San Mateo, California, USA.
  • Isaksson M; Helix, San Mateo, California, USA.
  • Washington NL; Helix, San Mateo, California, USA.
  • Basler T; Helix, San Mateo, California, USA.
  • Tsan K; Helix, San Mateo, California, USA.
  • Nguyen J; Helix, San Mateo, California, USA.
  • Ramirez J; Helix, San Mateo, California, USA.
  • Sandoval E; Helix, San Mateo, California, USA.
  • Lee W; Helix, San Mateo, California, USA.
  • Lu J; Helix, San Mateo, California, USA.
  • Luo S; Helix, San Mateo, California, USA.
J Infect Dis ; 2024 Jul 19.
Article in En | MEDLINE | ID: mdl-39028664
ABSTRACT
Within a multi-state viral genomic surveillance program, we evaluated whether proportions of SARS-CoV-2 infections attributed to the JN.1 variant and to XBB-lineage variants (including HV.1 and EG.5) differed between inpatient and outpatient care settings during periods of cocirculation. Both JN.1 and HV.1 were less likely than EG.5 to account for infections among inpatients versus outpatients (aOR=0.60 [95% CI 0.43-0.84; p=0.003] and aOR=0.35 [95% CI 0.21-0.58; p<0.001], respectively). JN.1 and HV.1 variants may be associated with a lower risk of severe illness. The severity of COVID-19 may have attenuated as predominant circulating SARS-CoV-2 lineages shifted from EG.5 to HV.1 to JN.1.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Infect Dis Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Infect Dis Year: 2024 Type: Article Affiliation country: United States